Certara (NASDAQ:CERT) Price Target Cut to $18.00

Certara (NASDAQ:CERT) had its price target lowered by Robert W. Baird from $19.00 to $18.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 39.53% from the company’s previous close.

CERT has been the topic of several other research reports. UBS Group dropped their price target on shares of Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Barclays dropped their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Finally, KeyCorp reduced their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $18.83.

Certara Stock Down 1.3 %

Shares of CERT stock traded down $0.17 during trading hours on Wednesday, hitting $12.90. 21,381 shares of the company were exchanged, compared to its average volume of 572,288. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26. Certara has a one year low of $11.81 and a one year high of $19.87. The business’s 50-day simple moving average is $15.02 and its two-hundred day simple moving average is $16.50. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -33.51, a P/E/G ratio of 5.39 and a beta of 1.52.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. Certara’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. Sell-side analysts predict that Certara will post 0.28 EPS for the current fiscal year.

Institutional Trading of Certara

Several institutional investors have recently made changes to their positions in the business. Mubadala Investment Co PJSC bought a new position in Certara during the 4th quarter valued at about $169,135,000. Franklin Resources Inc. grew its holdings in Certara by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 1,820,864 shares of the company’s stock valued at $32,029,000 after purchasing an additional 138,682 shares during the period. Sei Investments Co. grew its holdings in Certara by 12.4% during the first quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock valued at $12,793,000 after purchasing an additional 79,013 shares during the period. Edmond DE Rothschild Holding S.A. boosted its holdings in shares of Certara by 93.1% in the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock valued at $13,532,000 after buying an additional 370,820 shares during the last quarter. Finally, Norges Bank acquired a new stake in Certara in the fourth quarter valued at $14,262,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.